Cynthia V Calkin1, Martina Ruzickova1, Rudolf Uher1, Tomas Hajek1, Claire M Slaney1, Julie S Garnham1, M Claire O'Donovan1, Martin Alda1. 1. Cynthia V. Calkin, MD, CCFP, FRCPC, Martina Ruzickova, MD, PhD, FRCPC, Department of Psychiatry, Dalhousie University, Halifax, Canada; Rudolf Uher, MD, PhD, Department of Psychiatry, Dalhousie University, Halifax, Canada and Institute of Psychiatry, MRC Social, Genetic & Developmental Psychiatry Centre, King's College London, UK; Tomas Hajek, MD, PhD, Department of Psychiatry, Dalhousie University, Halifax, Canada and Department of Psychiatry, 3rd School of Medicine, Prague, Charles University, Czech Republic; Claire M. Slaney, RN, Julie S. Garnham, RNBN, Capital District Health Authority, Halifax, Canada; M. Claire O'Donovan, MB, FRCPC, Department of Psychiatry, Dalhousie University, Halifax, Canada; Martin Alda, MD, FRCPC, Department of Psychiatry, Dalhousie University, Halifax, Canada and Department of Psychiatry, 3rd School of Medicine, Prague, Charles University, Czech Republic.
Abstract
BACKGROUND: Little is known about the impact of insulin resistance on bipolar disorder. AIMS: To examine the relationships between insulin resistance, type 2 diabetes and clinical course and treatment outcomes in bipolar disorder. METHOD: We measured fasting glucose and insulin in 121 adults with bipolar disorder. We diagnosed type 2 diabetes and determined insulin resistance. The National Institute of Mental Health Life Chart was used to record the course of bipolar disorder and the Alda scale to establish response to prophylactic lithium treatment. RESULTS: Patients with bipolar disorder and type 2 diabetes or insulin resistance had three times higher odds of a chronic course of bipolar disorder compared with euglycaemic patients (50% and 48.7% respectively v. 27.3%, odds ratio (OR) = 3.07, P = 0.007), three times higher odds of rapid cycling (38.5% and 39.5% respectively v. 18.2%, OR = 3.13, P = 0.012) and were more likely to be refractory to lithium treatment (36.8% and 36.7% respectively v. 3.2%, OR = 8.40, P<0.0001). All associations remained significant after controlling for antipsychotic exposure and body mass index in sensitivity analyses. CONCLUSIONS: Comorbid insulin resistance may be an important factor in resistance to treatment in bipolar disorder. Royal College of Psychiatrists.
BACKGROUND: Little is known about the impact of insulin resistance on bipolar disorder. AIMS: To examine the relationships between insulin resistance, type 2 diabetes and clinical course and treatment outcomes in bipolar disorder. METHOD: We measured fasting glucose and insulin in 121 adults with bipolar disorder. We diagnosed type 2 diabetes and determined insulin resistance. The National Institute of Mental Health Life Chart was used to record the course of bipolar disorder and the Alda scale to establish response to prophylactic lithium treatment. RESULTS:Patients with bipolar disorder and type 2 diabetes or insulin resistance had three times higher odds of a chronic course of bipolar disorder compared with euglycaemic patients (50% and 48.7% respectively v. 27.3%, odds ratio (OR) = 3.07, P = 0.007), three times higher odds of rapid cycling (38.5% and 39.5% respectively v. 18.2%, OR = 3.13, P = 0.012) and were more likely to be refractory to lithium treatment (36.8% and 36.7% respectively v. 3.2%, OR = 8.40, P<0.0001). All associations remained significant after controlling for antipsychotic exposure and body mass index in sensitivity analyses. CONCLUSIONS: Comorbid insulin resistance may be an important factor in resistance to treatment in bipolar disorder. Royal College of Psychiatrists.
Authors: W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha Journal: Neurosci Biobehav Rev Date: 2018-02-02 Impact factor: 8.989
Authors: Sean R McWhinney; Christoph Abé; Martin Alda; Francesco Benedetti; Erlend Bøen; Caterina Del Mar Bonnin; Tiana Borgers; Katharina Brosch; Erick J Canales-Rodríguez; Dara M Cannon; Udo Dannlowski; Ana M Diaz-Zuluaga; Lorielle Dietze; Torbjørn Elvsåshagen; Lisa T Eyler; Janice M Fullerton; Jose M Goikolea; Janik Goltermann; Dominik Grotegerd; Bartholomeus C M Haarman; Tim Hahn; Fleur M Howells; Martin Ingvar; Tilo T J Kircher; Axel Krug; Rayus T Kuplicki; Mikael Landén; Hannah Lemke; Benny Liberg; Carlos Lopez-Jaramillo; Ulrik F Malt; Fiona M Martyn; Elena Mazza; Colm McDonald; Genevieve McPhilemy; Sandra Meier; Susanne Meinert; Tina Meller; Elisa M T Melloni; Philip B Mitchell; Leila Nabulsi; Igor Nenadic; Nils Opel; Roel A Ophoff; Bronwyn J Overs; Julia-Katharina Pfarr; Julian A Pineda-Zapata; Edith Pomarol-Clotet; Joaquim Raduà; Jonathan Repple; Maike Richter; Kai G Ringwald; Gloria Roberts; Alex Ross; Raymond Salvador; Jonathan Savitz; Simon Schmitt; Peter R Schofield; Kang Sim; Dan J Stein; Frederike Stein; Henk S Temmingh; Katharina Thiel; Sophia I Thomopoulos; Neeltje E M van Haren; Holly Van Gestel; Cristian Vargas; Eduard Vieta; Annabel Vreeker; Lena Waltemate; Lakshmi N Yatham; Christopher R K Ching; Ole A Andreassen; Paul M Thompson; Tomas Hajek Journal: Bipolar Disord Date: 2021-12-16 Impact factor: 5.345
Authors: Rodrigo B Mansur; Francheska Delgado-Peraza; Mehala Subramaniapillai; Yena Lee; Michelle Iacobucci; Flora Nasri; Nelson Rodrigues; Joshua D Rosenblat; Elisa Brietzke; Victoria E Cosgrove; Nicole E Kramer; Trisha Suppes; Charles L Raison; Andrea Fagiolini; Natalie Rasgon; Sahil Chawla; Carlos Nogueras-Ortiz; Dimitrios Kapogiannis; Roger S McIntyre Journal: J Psychiatr Res Date: 2020-12-04 Impact factor: 4.791